echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Orphan Drug Weekly | Selective IL-2 agonists and other 4 research therapies are shortlisted

    Orphan Drug Weekly | Selective IL-2 agonists and other 4 research therapies are shortlisted

    • Last Update: 2021-03-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Last week, the FDA issued a total of 4 orphan drug qualifications, including 3 small molecule targeted drugs and 1 fusion protein, including the IL-2 selective agonist nemvaleukin alfa (ALKS 4230) developed by Alkermes to treat mucosal melanoma.


    Drug: Nemvaleukin alfa

    R&D company: Alkermes

    Treatment of disease: mucosal melanoma (mucosal melanoma)

    Introduction: Nemvaleukin alfa is an innovative engineering fusion protein under research, which is composed of modified interleukin-2 (IL-2) and a high-affinity IL-2α receptor chain, designed to selectively amplify tumor-killing effects Immune cells, while avoiding activating immunosuppressive cells.


    Drug: Ubenimex (ubenimex)

    Research and development company: RNR BioMedical

    Treatment of diseases: chronic myeloid leukemia (CML)

    Introduction: Chronic myelogenous leukemia (CML) is a malignant myeloproliferative tumor that occurs on pluripotent hematopoietic stem cells.


    Note: This article is intended to introduce medical and health research, not a treatment plan recommendation.


    Reference materials:

    [1] Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma.


    [2]Ubenimex.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.